{
  "Figure": "1-s2.0-S1556086415320426-main_page5_61.jpg",
  "Figure_title": "a radiation dose escalation study. Int J Radiat Oncol Biol Phys 2005; 63:324–333. 3. Rosenzweig KE, Fox JL, Yorke E, et al. Results of a phase I dose- escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. Cancer 2005;103: 2118–2127. 4. Bradley J, Graham MV, Winter K, et al. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2005;61:318–328. 5. Anscher MS, Kong FM, Marks LB, et al. Changes in plasma transform- ing growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis. Int J Radiat Oncol Biol Phys 1997;37: 253–258. 6. Fu XL, Huang H, Bentel G, et al. Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V(30) and transforming growth factor beta. Int J Radiat Oncol Biol Phys 2001;50:899–908. 7. Kong FM, Ten Haken R, Eisbruch A, et al. Non-small cell lung cancer therapy-related pulmonary toxicity: an update on radiation pneumonitis and ﬁbrosis. Semin Oncol 2005;32:S42–S54. 8. Sung HJ, Cho JY. Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep 2008;41:615–625. 9. Latterich M, Abramovitz M, Leyland-Jones B. Proteomics: new tech- nologies and clinical applications. Eur J Cancer 2008;44:2737–2741. 10. Koomen JM, Haura EB, Bepler G, et al. Proteomic contributions to personalized cancer care. Mol Cell Proteomics 2008;7:1780–1794. 11. Conrad DH, Goyette J, Thomas PS. Proteomics as a method for early detection of cancer: a review of proteomics, exhaled breath condensate, and lung cancer screening. J Gen Inter Med 2008;23:78–84. 12. Patz EF Jr, Campa MJ, Gottlin EB, et al. Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol 2007;25:5578–5583. 13. Malard V, Prat O, Darrouzet E, et al. Proteomic analysis of the response of human lung cells to uranium. Proteomics 2005;5:4568–4580. 14. Me´nard C, Johann D, Lowenthal M, et al. Discovering clinical biomark- ers of ionizing radiation exposure with serum proteomic analysis. Can- cer Res 2006;66:1844–1850. 15. Xu NY, Zhang SP, Nie JH, et al. Radon-induced proteomic proﬁle of lung tissue in rats. J Toxicol Environ Health A 2008;71:361–366. 16. Ao X, Lubman DM, Davis MA, et al. Comparative proteomic analysis of radiation-induced changes in mouse lung: ﬁbrosis-sensitive and -re- sistant strains. Radiat Res 2008;169:417–425. 17. Cai XW, Shedden K, Ao X, et al. Plasma proteomic analysis may identify new markers for radiation-induced lung toxicity in patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2010;77:867– 876. 18. Chapet O, Kong FM, Quint LE, et al. CT-based deﬁnition of thoracic lymph node stations: an atlas from the University of Michigan. Int J Radiat Oncol Biol Phys 2005;63:170–178. 19. Kong FM, Hayman JA, Grifﬁth KA, et al. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and ﬁbrosis. Int J Radiat Oncol Biol Phys 2006;65:1075–1086. 20. Sano K, Asanuma-Date K, Arisaka F, et al. Changes in glycosylation of vitronectin modulate multimerization and collagen binding during liver regeneration. Glycobiology 2007;17:784–794. 21. Chung LP, Bentley DR, Reid KB. Molecular cloning and characteriza- tion of the cDNA coding for C4b-binding protein, a regulatory protein of the classical pathway of the human complement system. Biochem J 1985;230:133–141. "
}